文献速递腹部技术与安全US

美国肝脏影像报告和数据系统2017版超声部分:系统综述与Meta分析

US Liver Imaging Reporting and Data System Version 2017: A Systematic Review and Meta-Analysis.
PubMed 文献 · Radiology · 2025-01-01

该系统综述与Meta分析纳入15项研究共39166次超声检查,评估美国LI-RADS 2017版超声分类与可视化评分的分布。89.7%为US-1,5.9%为US-3,US-3中25.9%为可能或确诊肝细胞癌;59.7%为VIS-A,7.8%为VIS-C,VIS-C与肥胖、非酒精性脂肪性肝病及Child-Pugh B或C相关。

要点

  • US-3仅占5.9%,其中25.9%为可能或确诊肝细胞癌,26.4%为总体恶性肿瘤。
  • VIS-C仅占7.8%,与肥胖、非酒精性脂肪性肝病及Child-Pugh B或C相关。
  • 约90%监测超声为US-1阴性,92%图像质量达VIS-A或VIS-B。

核心结论

  • 约90%监测超声结果为US-1阴性,92%图像质量达VIS-A或VIS-B;US-3结果中26%患者有肝细胞癌;VIS-C与肥胖、非酒精性脂肪性肝病及肝硬化相关。

研究设计与样本

  • 系统综述与Meta分析,检索2017年1月1日至2023年9月17日发表文献,纳入15项研究共39166次超声检查,采用随机效应模型合并估计。

关键影像表现/征象

  • 全部检查中89.7%(95%CI:86.8,91.8)为US-1,4.4%(95%CI:2.8,6.2)为US-2,5.9%(95%CI:4.1,8.0)为US-3。
  • US-3检查中25.9%(95%CI:17.1,34.7)为可能或确诊肝细胞癌,26.4%(95%CI:18.4,34.5)为总体恶性肿瘤。
  • 全部检查中59.7%(95%CI:46.9,67.8)为VIS-A,32.5%(95%CI:21.9,41.6)为VIS-B,7.8%(95%CI:2.8,14.3)为VIS-C。

诊断标准与关键数值

  • US LI-RADS 2017版评估分类:US-1为阴性,US-2为低于阈值,US-3为阳性。
  • 可视化评分:VIS-A为无或轻微限制,VIS-B为中度限制,VIS-C为严重限制。
  • 肥胖与VIS-C相关(OR 2.37;95%CI:1.57,3.59),非酒精性脂肪性肝病与VIS-C相关(OR 2.24;95%CI:1.64,3.06),Child-Pugh B或C与VIS-C相关(OR 2.41;95%CI:1.43,4.06)。

临床应用与阅片要点

  • US-3仅占5.9%,但其中约四分之一为肝细胞癌,报告US-3时需结合临床进一步评估。
  • VIS-C仅占7.8%,与肥胖、非酒精性脂肪性肝病及Child-Pugh B或C相关,提示这些患者图像质量可能受限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The US Liver Imaging Reporting and Data System (LI-RADS) includes an assessment category (US-1, negative; US-2, subthreshold; and US-3, positive) and a visualization score reflecting image quality (VIS-A, no or minimal limitations; VIS-B, moderate limitations; and VIS-C, severe limitations). The US-3 and VIS-C impact patient treatment. Purpose To establish the distributions of categories and visualization scores, estimate the proportions of hepatocellular carcinoma (HCC) and overall malignancy in the US-3 category, and identify variables associated with the VIS-C score by conducting a meta-analysis. Materials and Methods A systematic search of articles published between January 1, 2017, and September 17, 2023, identified studies reporting distributions of US LI-RADS version 2017 categories or visualization scores. Characteristics of the study design, patient cohorts, and outcomes of interest (distributions of US categories and visualization scores, percentages of probable or definite HCC and malignancy in US-3 category, and variables associated with VIS-C) were extracted. For the meta-analysis, estimates were established with random-effects models. Results Fifteen studies comprising 39 166 US examinations were included. Of all examinations, 89.7% (95% CI: 86.8, 91.8) were categorized US-1; 4.4% (95% CI: 2.8, 6.2), US-2; and 5.9% (95% CI: 4.1, 8.0), US-3. Of the US-3 examinations, 25.9% (95% CI: 17.1, 34.7) had probable or definite HCC and 26.4% (95% CI: 18.4, 34.5) had overall malignancy. Among all examinations, 59.7% (95% CI: 46.9, 67.8) were assigned VIS-A; 32.5% (95% CI: 21.9, 41.6), VIS-B; and 7.8% (95% CI: 2.8, 14.3), VIS-C. Obesity (odds ratio [OR], 2.37; 95% CI: 1.57, 3.59), nonalcoholic fatty liver disease (NAFLD) (OR, 2.24; 95% CI: 1.64, 3.06), and Child-Pugh B or C (OR, 2.41; 95% CI: 1.43, 4.06) were associated with VIS-C score. Conclusion Overall, 90% of surveillance US results were negative (US-1), and 92% were of adequate quality (VIS-A or VIS-B); 26% of patients with US-3 results had HCC. VIS-C was associated with obesity, NAFLD, and cirrhosis. Systemic review registry no. CRD42022384925 © RSNA, 2025 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Lee S, Yoon JK, Shin J, et al. US Liver Imaging Reporting and Data System Version 2017: A Systematic Review and Meta-Analysis. Radiology. 2025. PMID: 40067102. doi:10.1148/radiol.240450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。